因此，在CCCG-ALL-2015、CCCG-ALL-2020多中心研究队列、同时研究结果和最新临床试验结果的基础上，开发了CCCG-ALL-2025 I/HR-B-ALL ，以进一步改善中高风险B细胞儿童急性淋巴母细胞白血病（ I/HR-B-ALL ）儿童的无事件生存期（ EFS ）、总生存期（ OS ）和生活质量（ QOL ） ，同时减少不良反应和移植
适应症：Acute Lymphoblastic Leukemia ALL、Childhood Leukemia, Acute Lymphoblastic、B Cell Acute Lymphoblastic Leukemia (B-ALL)
入组条件
纳入标准
- Age older than 1 month to younger than 18 years.
- Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.
- Diagnosis of B-ALL by immunophenotyping.
排除标准
- Low-risk ALL
- sIgM+
- Acute leukemias of ambiguous lineage diagnosed according to WHO or EGIL criteria.
- ALL evolved from chronic myeloid leukemia (CML).
- Down's syndrome, or major congenital or hereditary disease with organ dysfunction
- Secondary leukemia
- Known underlying congenital immunodeficiency or metabolic disease
- Congenital heart disease with cardiac insufficiency.
- Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。